65460
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 32
- fusion
- ZFTA_RELA
- e1_e2
- E2
- umap1_2d
- -5.579017501
- umap2_2d
- 2.124329261
- umap1_3d
- 0.418378044
- umap2_3d
- 1.017936964
- umap3_3d
- -1.905967056
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.440
- E2F_TARGETS+0.410
- G2M_CHECKPOINT+0.340
- MYC_TARGETS_V1+0.310
- MTORC1_SIGNALING+0.280
- UV_RESPONSE_DN+0.270
- PANCREAS_BETA_CELLS+0.230
- ANDROGEN_RESPONSE+0.220
- KRAS_SIGNALING_UP+0.220
- PROTEIN_SECRETION+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- INTERFERON_GAMMA_RESPONSE-0.350
- P53_PATHWAY-0.260
- MYC_TARGETS_V2-0.190
- TNFA_SIGNALING_VIA_NFKB-0.160
- HEME_METABOLISM-0.110
- HYPOXIA-0.090
- ESTROGEN_RESPONSE_EARLY-0.080
- DNA_REPAIR-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013587 | — | cohortA3 | 0.758 |
| 2 | BS_EVCAC3NH | EPN | Supratentorial EPN | 0.746 |
| 3 | SRR1516047 | — | — | 0.745 |
| 4 | TCGA-96-7544-01A-11R-2045-07 | — | cohortSQ1 | 0.743 |
| 5 | DRR168567 | — | — | 0.720 |
| 6 | MNG2 | — | — | 0.710 |
| 7 | MNG56 | — | — | 0.709 |
| 8 | c45adda2-fffe-4add-8148-01ecf35dd855 | — | — | 0.697 |
| 9 | TCGA-CV-7102-01A-11R-2016-07 | — | — | 0.694 |
| 10 | DRR168514 | — | — | 0.691 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.140 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |
| COMPLEMENT | 0.070 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.070 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |